Thermo Fisher Scientific revenue was $39.21 b in FY, 2021 which is a 21.7% year over year increase from the previous period.
Thermo Fisher Scientific revenue breakdown by business segment: 37.0% from Life Sciences Solutions, 14.4% from Analytical Instruments, 13.4% from Specialty Diagnostics and 35.2% from Laboratory Products and Services
Thermo Fisher Scientific revenue breakdown by geographic segment: 8.8% from China, 48.2% from United States and 43.0% from Other
USD | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|
Revenue | 25.5b | 32.2b | 39.2b |
Revenue growth, % | 5% | 26% | 22% |
Cost of goods sold | 14.2b | 16.2b | 19.6b |
Gross profit | 11.3b | 16.0b | 19.6b |
Gross profit Margin, % | 44% | 51% | 50% |
R&D expense | 1.0b | 1.2b | 1.4b |
General and administrative expense | 6.1b | 6.9b | 8.0b |
Operating expense total | 6.7b | 8.2b | 9.6b |
EBIT | 4.6b | 7.8b | 10.0b |
EBIT margin, % | 18% | 24% | 26% |
Interest expense | 676.0m | 553.0m | 536.0m |
Interest income | 224.0m | 65.0m | 43.0m |
Pre tax profit | 4.1b | 7.2b | 8.8b |
Income tax expense | 374.0m | 850.0m | 1.1b |
Net Income | 3.7b | 6.4b | 7.7b |
EPS | 9.2 | 16.0 | 19.5 |
USD | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|
Revenue | 6.2b | 6.9b | 8.5b | 9.9b | 9.3b | 9.3b | 11.8b |
Cost of goods sold | 3.5b | 3.5b | 4.2b | 4.7b | 4.7b | 4.7b | 6.4b |
Gross profit | 2.7b | 3.4b | 4.3b | 5.2b | 4.5b | 4.7b | 5.5b |
Gross profit Margin, % | 44% | 51% | 51% | 53% | 49% | 50% | 46% |
R&D expense | 245.0m | 264.0m | 296.0m | 320.0m | 343.0m | 351.0m | 364.0m |
General and administrative expense | 1.6b | 1.7b | 1.6b | 1.8b | 1.9b | 2.0b | 2.3b |
Operating expense total | 1.8b | 2.0b | 1.9b | 2.2b | 2.4b | 2.4b | 2.6b |
EBIT | 906.0m | 1.4b | 2.4b | 3.0b | 2.2b | 2.3b | 2.8b |
EBIT margin, % | 15% | 20% | 28% | 31% | 23% | 24% | 24% |
Interest expense | 126.0m | 137.0m | 144.0m | 125.0m | 122.0m | 128.0m | 136.0m |
Interest income | 36.0m | 8.0m | 9.0m | 12.0m | 11.0m | 9.0m | 18.0m |
Pre tax profit | 828.0m | 1.3b | 2.3b | 2.8b | 2.0b | 2.2b | 2.5b |
Income tax expense | 40.0m | 97.0m | 319.0m | 416.0m | 219.0m | 271.0m | 301.0m |
Net Income | 788.0m | 1.2b | 1.9b | 2.3b | 1.8b | 1.9b | 2.2b |
EPS | 2.0 | 2.9 | 4.8 | 5.9 | 4.6 | 4.8 | 5.6 |
USD | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|
Cash | 2.4b | 10.3b | 4.5b |
Accounts Receivable | 4.3b | 5.7b | 8.0b |
Inventories | 3.4b | 4.0b | 5.1b |
Current Assets | 11.9b | 22.0b | 20.1b |
PP&E | 4.7b | 5.9b | 8.3b |
Goodwill | 25.7b | 26.0b | 41.9b |
Total Assets | 58.4b | 69.1b | 95.1b |
Accounts Payable | 1.9b | 2.2b | 2.9b |
Short-term debt | 676.0m | 2.6b | 2.5b |
Current Liabilities | 6.2b | 10.3b | 13.4b |
Long-term debt | 17.1b | 19.1b | 32.3b |
Total Debt | 17.8b | 21.7b | 34.9b |
Total Liabilities | 28.7b | 34.5b | 54.1b |
Common Stock | 434.0m | 437.0m | 439.0m |
Additional Paid-in Capital | 15.1b | 15.6b | 16.2b |
Retained Earnings | 22.1b | 28.1b | 35.4b |
Total Equity | 29.7b | 34.5b | 40.9b |
Debt to Equity Ratio | 0.6 x | 0.6 x | 0.9 x |
Debt to Assets Ratio | 0.3 x | 0.3 x | 0.4 x |
Financial Leverage | 2 x | 2 x | 2.3 x |
USD | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|
Net Income | 3.7b | 6.4b | 7.7b |
Depreciation and Amortization | 2.3b | 2.3b | 2.6b |
Accounts Receivable | (225.0m) | (1.3b) | (204.0m) |
Inventories | (458.0m) | (508.0m) | (1.1b) |
Accounts Payable | 266.0m | 59.0m | 479.0m |
Cash From Operating Activities | 5.0b | 8.3b | 9.3b |
Purchases of PP&E | (926.0m) | (1.5b) | (2.5b) |
Cash From Investing Activities | (1.5b) | (1.5b) | (21.9b) |
Long-term Borrowings | (9.8b) | (1.1b) | (11.7b) |
Dividends Paid | (297.0m) | (337.0m) | (395.0m) |
Cash From Financing Activities | (3.1b) | 959.0m | 6.6b |
Net Change in Cash | 305.0m | 7.9b | (5.8b) |
Interest Paid | 790.0m | 471.0m | 555.0m |
Income Taxes Paid | 896.0m | 1.3b | 2.2b |
USD | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|
Net Income | 788.0m | 1.9b | 3.9b | 2.3b | 4.2b | 6.1b | 2.2b |
Depreciation and Amortization | 574.0m | 1.1b | 1.7b | 621.0m | 1.3b | (614.0m) | 859.0m |
Accounts Receivable | (218.0m) | (195.0m) | (858.0m) | 149.0m | 249.0m | 111.0m | |
Inventories | (141.0m) | (309.0m) | (427.0m) | (352.0m) | (621.0m) | 916.0m | 499.0m |
Accounts Payable | (241.0m) | (497.0m) | (220.0m) | ||||
Cash From Operating Activities | 356.0m | 2.2b | 5.0b | 2.0b | 4.2b | 6.9b | 2.2b |
Purchases of PP&E | (253.0m) | (522.0m) | (888.0m) | (628.0m) | (1.2b) | (1.7b) | (640.0m) |
Cash From Investing Activities | (260.0m) | (519.0m) | (884.0m) | (2.0b) | (2.6b) | (3.2b) | (670.0m) |
Short-term Borrowings | (1.3b) | ||||||
Long-term Borrowings | (322.0m) | (389.0m) | (1.1b) | (2.8b) | (2.8b) | (2.8b) | (375.0m) |
Dividends Paid | (76.0m) | (163.0m) | (250.0m) | (87.0m) | (190.0m) | (292.0m) | (103.0m) |
Cash From Financing Activities | 619.0m | 1.8b | 1.0b | (4.8b) | (4.9b) | (1.9b) | (3.1b) |
Net Change in Cash | 588.0m | 3.4b | 5.1b | (4.7b) | (3.3b) | 1.7b | (1.7b) |
Income Taxes Paid | 100.0m | 320.0m | 656.0m | 542.0m | 1.3b | 1.6b | 303.0m |
USD | FY, 2019 |
---|---|
EV/EBIT | 31.7 x |
EV/CFO | 29.3 x |
Revenue/Employee | 340.6k |
Debt/Equity | 0.6 x |
Debt/Assets | 0.3 x |
Financial Leverage | 2 x |
P/E Ratio | 35.4 |
FY, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | FY, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | FY, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | FY, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Customers | 400 k | 400 k | 400 k | ||||||||||
Remaining Performance Obligations | $5.09 b | $5.57 b | $7.07 b | $6.76 b | $7.77 b | $8.36 b | $9.99 b | $11.16 b | $12.81 b | $13.29 b | $13.56 b | $14.49 b | $28.3 b |
Backlog | $5.09 b | $7.77 b | |||||||||||
Backlog (Life Sciences Solutions) | $647 m | $893 m | |||||||||||
Backlog (Analytical Instruments) | $2.24 b | $2.2 b | |||||||||||
Backlog (Specialty Diagnostics) | $187 m | $172 m | |||||||||||
Backlog (Laboratory Products and Services) | $2.06 b | $4.58 b |
FY, 2020 | FY, 2019 | |
---|---|---|
Female, percent | 10.1% | 40.4% |
Male (Leadership, USA), percent | 15.8% | |
Male, percent | 14.4% | 58.8% |
Female (Leadership, USA), percent | 9.3% | |
Female (Executive Management, USA), percent | 7.5% | |
Male (USA), percent | 14.7% | |
Female (USA), percent | 10.3% | |
Male (Executive Management, USA), percent | 17.5% | |
Other | 0.6% | 0.8% |
FY, 2020 | |
---|---|
Other Ethnicity (USA), percent | 21.2% |
Other Ethnicity (Leadership, USA), percent | 24.8% |
Ethnic Minorities (Executive Management, USA), percent | 7.4% |
People of Color (USA), percent | 12.1% |
People of Color (Leadership, USA), percent | 8.5% |
Ethnic Non-Minorities (Executive Management, USA), percent | 26% |